Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : GLGC Gene Logic -- Ignore unavailable to you. Want to Upgrade?

To: Mike McFarland who wrote (262)	2/5/2007 5:04:13 PM
From: Mike McFarland	Respond to of 360

more OT Caliper For higher content screening, Caliper is working to develop a cell assay plate, combining microfluidics with a microplate format. This assay will allow generation of real -time dose-response curves with 12 different doses, and is expected to be launched in early 2007.” genengnews.com No point here, Caliper looks interesting enough to read the thread (which I haven't done yet).

To: Mike McFarland who wrote (262)	2/5/2007 5:17:53 PM
From: tuck	Read Replies (1) \| Respond to of 360

OT Re: Caliper "Ultimately we plan to go into models for human prediction.” Sounds great, but Xenogen won't help them there -- at least, not directly. It's no accident Xenogen uses mice: the light from luciferase only goes through so much protoplasm before fading away from the limits of detectability by CCD cameras. It wouldn't work in humans except maybe for skin diseases. To the extent Hrusovsky is referring to better mouse models of human disease, OK. To this point, I haven't thought of CALP's acquisition strategy as supporting some grand unified vision of drug discovery platforms. More a fractured "Well these guys are cash flow positive (Zymark) -- or almost (Xenogen)" financial vision. But I admit I haven't been paying close attention of late. Maybe it's more unified than I think. Last I checked there is still an IP issue for XGEN, versus San Diego's privately held AntiCancer (see the XGEN thread for details). My opinion was that they would win or cross-license on reasonable terms, but I haven't seen anything since CALP munched them. The current status is most likely buried deep in a CALP filing. Edit: and here's the update: Message 23255480 Cheers, Tuck